Cargando…
Estrogen modulation of cortical spreading depression
BACKGROUND AND AIMS: Cortical spreading depression (CSD), a transient neuronal and glial depolarization that propagates slowly across the cerebral cortex, is the putative electrophysiological event underlying migraine aura and a headache trigger. Migraine is three times more prevalent in women than...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214707/ https://www.ncbi.nlm.nih.gov/pubmed/37237336 http://dx.doi.org/10.1186/s10194-023-01598-x |
_version_ | 1785047893594341376 |
---|---|
author | Kudo, Chiho Harriott, Andrea M. Moskowitz, Michael A. Waeber, Christian Ayata, Cenk |
author_facet | Kudo, Chiho Harriott, Andrea M. Moskowitz, Michael A. Waeber, Christian Ayata, Cenk |
author_sort | Kudo, Chiho |
collection | PubMed |
description | BACKGROUND AND AIMS: Cortical spreading depression (CSD), a transient neuronal and glial depolarization that propagates slowly across the cerebral cortex, is the putative electrophysiological event underlying migraine aura and a headache trigger. Migraine is three times more prevalent in women than men, linked to circulating female hormones. High estrogen levels or estrogen withdrawal may be a migraine trigger for many women. We, therefore, aimed to examine whether sex, gonadectomy, and female hormone supplementation and withdrawal affect the susceptibility to CSD. METHODS: To determine CSD susceptibility, we recorded the frequency of CSDs triggered during 2-h topical KCl application in intact or gonadectomized female and male rats, without or with estradiol or progesterone supplementation via daily intraperitoneal injections. Estrogen or progesterone treatment followed by withdrawal was studied in a separate cohort. To take the first step towards identifying potential mechanisms, we studied glutamate and GABA(A) receptor binding using autoradiography. RESULTS: The CSD frequency in intact female rats was higher than intact male and ovariectomized rats. We did not detect a change in CSD frequency during different stages of the estrous cycle in intact females. Daily estrogen injections for three weeks did not change CSD frequency. However, one-week estrogen withdrawal after two weeks of treatment significantly increased CSD frequency compared with the vehicle group in gonadectomized females. The same protocol of estrogen treatment and withdrawal was ineffective in gonadectomized males. In contrast to estrogen, daily progesterone injections for three weeks elevated CSD susceptibility, and one-week withdrawal after two weeks of treatment partially normalized this effect. Autoradiography did not reveal significant changes in glutamate or GABA(A) receptor binding density after estrogen treatment and withdrawal. CONCLUSIONS: These data suggest that females are more susceptible to CSD, and sexual dimorphism is abrogated by gonadectomy. Moreover, estrogen withdrawal after prolonged daily treatment enhances CSD susceptibility. These findings may have implications for estrogen-withdrawal migraine, although the latter tends to be without aura. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10194-023-01598-x. |
format | Online Article Text |
id | pubmed-10214707 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Milan |
record_format | MEDLINE/PubMed |
spelling | pubmed-102147072023-05-27 Estrogen modulation of cortical spreading depression Kudo, Chiho Harriott, Andrea M. Moskowitz, Michael A. Waeber, Christian Ayata, Cenk J Headache Pain Research BACKGROUND AND AIMS: Cortical spreading depression (CSD), a transient neuronal and glial depolarization that propagates slowly across the cerebral cortex, is the putative electrophysiological event underlying migraine aura and a headache trigger. Migraine is three times more prevalent in women than men, linked to circulating female hormones. High estrogen levels or estrogen withdrawal may be a migraine trigger for many women. We, therefore, aimed to examine whether sex, gonadectomy, and female hormone supplementation and withdrawal affect the susceptibility to CSD. METHODS: To determine CSD susceptibility, we recorded the frequency of CSDs triggered during 2-h topical KCl application in intact or gonadectomized female and male rats, without or with estradiol or progesterone supplementation via daily intraperitoneal injections. Estrogen or progesterone treatment followed by withdrawal was studied in a separate cohort. To take the first step towards identifying potential mechanisms, we studied glutamate and GABA(A) receptor binding using autoradiography. RESULTS: The CSD frequency in intact female rats was higher than intact male and ovariectomized rats. We did not detect a change in CSD frequency during different stages of the estrous cycle in intact females. Daily estrogen injections for three weeks did not change CSD frequency. However, one-week estrogen withdrawal after two weeks of treatment significantly increased CSD frequency compared with the vehicle group in gonadectomized females. The same protocol of estrogen treatment and withdrawal was ineffective in gonadectomized males. In contrast to estrogen, daily progesterone injections for three weeks elevated CSD susceptibility, and one-week withdrawal after two weeks of treatment partially normalized this effect. Autoradiography did not reveal significant changes in glutamate or GABA(A) receptor binding density after estrogen treatment and withdrawal. CONCLUSIONS: These data suggest that females are more susceptible to CSD, and sexual dimorphism is abrogated by gonadectomy. Moreover, estrogen withdrawal after prolonged daily treatment enhances CSD susceptibility. These findings may have implications for estrogen-withdrawal migraine, although the latter tends to be without aura. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s10194-023-01598-x. Springer Milan 2023-05-26 /pmc/articles/PMC10214707/ /pubmed/37237336 http://dx.doi.org/10.1186/s10194-023-01598-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kudo, Chiho Harriott, Andrea M. Moskowitz, Michael A. Waeber, Christian Ayata, Cenk Estrogen modulation of cortical spreading depression |
title | Estrogen modulation of cortical spreading depression |
title_full | Estrogen modulation of cortical spreading depression |
title_fullStr | Estrogen modulation of cortical spreading depression |
title_full_unstemmed | Estrogen modulation of cortical spreading depression |
title_short | Estrogen modulation of cortical spreading depression |
title_sort | estrogen modulation of cortical spreading depression |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214707/ https://www.ncbi.nlm.nih.gov/pubmed/37237336 http://dx.doi.org/10.1186/s10194-023-01598-x |
work_keys_str_mv | AT kudochiho estrogenmodulationofcorticalspreadingdepression AT harriottandream estrogenmodulationofcorticalspreadingdepression AT moskowitzmichaela estrogenmodulationofcorticalspreadingdepression AT waeberchristian estrogenmodulationofcorticalspreadingdepression AT ayatacenk estrogenmodulationofcorticalspreadingdepression |